Released May 8, 2014, after the close
10-Q filed May 8, 2014, 38 days after period end · 0001144204-14-028653
Q1 2014 · 10-Q
Revenue$6.70M$6.70M +87.7% vs Q1 2013no prior Q4 2013 on file
Net Income-$7.35M-$7.35M N/M vs Q1 2013N/M vs Q4 2013
EPS Diluted$0.08$0.08 +60.0% vs Q1 2013no prior Q4 2013 on file
Gross Profit$3,310,000+10.4%
Operating Income-$6,468,000N/M
Operating Cash Flow-$8,340,000N/M
Free Cash Flowderived-$8,603,000N/M
Margins · derived
Gross margin49.4%−34.6 pt vs Q1 2013
Operating margin-96.6%+27.5 pt vs Q1 2013
Net margin-109.7%+11.4 pt vs Q1 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2014 | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|---|
| Revenue | $6.70M | $3.57M | $3.86M | — |
| Net Income | -$7.35M | -$4.32M | -$5.90M | -$5.05M |
| EPS Diluted | $0.08 | $0.05 | $0.07 | $0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR